Thursday, April 9, 2026

Neogen raises FY26 revenue guidance and agrees to sell global Genomics business to Zoetis

 


  • Neogen reported fiscal third-quarter 2026 results in conjunction with its guidance increase and Genomics divestiture announcement.
  • Neogen entered a definitive $160 million agreement to sell its global Genomics business to Zoetis.
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.